Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.25.1 (
deoxyribonuclease
)
1,471
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study sought to estimate the applicability of apurinic/apyrimidinic
endodeoxyribonuclease
1 (APE1), vascular endothelial growth factor A (VEGFA) expression and
CD163
+
tumor-associated macrophage (TAM) ratio as prognostic factors in bladder cancer (BCa). A total of 127 patients with bladder urothelial cancer who underwent radical cystectomy at Daping Hospital were recruited between January 2013 and January 2017, including 45 cases of non-muscle invasive BCa (NMIBC) and 82 of MIBC. Immunohistochemical detection of APE1, VEGFA and
CD163
, as well as multiple immunofluorescence staining for APE1, VEGFA,
CD163
and CD34, were performed on tissue samples. For APE1 and VEGFA, the staining was graded based on intensity (0-3), while
CD163
was graded (0-3) based on the percentage of positively stained cells. The prognostic value of APE1, VEGF and
CD163
was assessed using Kaplan-Meier and Cox regression analysis. The results suggested that in BCa, high APE1 expression was associated with high VEGFA expression and more infiltration of
CD163
+
TAM. Furthermore, high expression of APE1 was associated with lymphovascular invasion of BCa, as well as reduced survival time. This indicates that APE1 may be associated with
CD163
+
TAM infiltration in BCa, with VEGFA as a possible influencing factor.
...
PMID:Correlation of APE1 with VEGFA and CD163
+
macrophage infiltration in bladder cancer and their prognostic significance. 3278 4